Trial Profile
A multi-center, randomized, double-blind, double-dummy study in postmenopausal women with low bone mineral density to compare the effects of a single dose of i.v. [intravenous] zoledronic acid 5 mg, with daily oral raloxifene 60 mg OD [once daily] on bone turnover markers.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary) ; Raloxifene
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Novartis
- 11 Sep 2009 Results presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research.
- 16 Dec 2008 Actual trial completion date identified as July 2008 from ClinicalTrials.gov.
- 16 Dec 2008 Actual patient number identified as 110 from ClinicalTrials.gov.